Belite Bio (BLTE) CFO Chuang Hao-Yuan details options and shares in Form 3

Rhea-AI Filing Summary

Belite Bio, Inc. director and Chief Financial Officer Chuang Hao-Yuan filed a Form 3 disclosing his existing equity holdings in the company. The filing lists several stock options to acquire ordinary shares, including options over 144,868 shares at an exercise price of $0.4386 per share expiring on December 22, 2030, and 26,112 shares at $6.00 per share expiring on April 17, 2032.

Additional options cover 120,834 ordinary shares at $14.45, 250,000 shares at $48.46, 200,000 shares at $54.88, 40,000 shares at $77.40, 80,000 shares at $93.02, and 150,000 shares at $158.36, each with expirations between 2033 and 2036. The filing also reports direct holdings of 100,000 American depositary shares and 195,264 ordinary shares, with each ADS representing one ordinary share.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Chuang Hao-Yuan

(Last) (First) (Middle)

12750 HIGH BLUFF DRIVE, SUITE 475

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
BELITE BIO, INC [ BLTE ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
American depositary share(1)	100,000	D
Ordinary Share	195,264	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(2)	12/22/2030	Ordinary Shares	144,868	$0.4386	D
Stock Option (right to buy)	(3)	04/17/2032	Ordinary Shares	26,112	$6	D
Stock Option (right to buy)	(4)	07/16/2033	Ordinary Shares	120,834	$14.45	D
Stock Option (right to buy)	(5)	08/28/2034	Ordinary Shares	250,000	$48.46	D
Stock Option (right to buy)	(6)	02/11/2035	Ordinary Shares	200,000	$54.88	D
Stock Option (right to buy)	(7)	10/06/2035	Ordinary Shares	40,000	$77.4	D
Stock Option (right to buy)	(8)	10/27/2035	Ordinary Shares	80,000	$93.02	D
Stock Option (right to buy)	(9)	01/08/2036	Ordinary Shares	150,000	$158.36	D

Explanation of Responses:

1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the Issuer.

2. The option to purchase 144,868 ordinary shares had vested prior to March 18, 2026.

3. The option to purchase 26,112 ordinary shares had vested prior to March 18, 2026.

4. The option to purchase 100,000 ordinary shares had vested prior to March 18, 2026. The option shall vest as to the remaining 20,834 ordinary shares in five monthly equal and continuous installments at the end of each month from March 2026 to July 2026, subject to continued service to the Issuer on each such date.

5. The option shall vest as to 250,000 ordinary shares in 36 equal and continuous monthly installments for each full month of services completed following August 29, 2024, subject to continued service to the Issuer on each such date.

6. The option shall vest as to 200,000 ordinary shares in 36 equal and continuous monthly installments for each full month of services completed following February 12, 2025, subject to continued service to the Issuer on each such date.

7. The option to purchase 40,000 ordinary shares had vested prior to March 18, 2026.

8. The option to purchase 80,000 ordinary shares had vested prior to March 18, 2026.

9. The option shall vest (i) as to 50,000 ordinary shares on January 9, 2027, (ii) as to 50,000 ordinary shares on January 9, 2028, and (iii) as to 50,000 ordinary shares on January 9, 2029.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Hao-Yuan Chuang	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Belite Bio (BLTE) CFO Chuang Hao-Yuan report in this Form 3?

He reports his existing equity holdings in Belite Bio, including stock options and common equity. The filing lists multiple option grants over ordinary shares plus direct ownership of American depositary shares and ordinary shares, giving investors a snapshot of his baseline ownership position.

What stock options does the Belite Bio (BLTE) CFO hold according to the Form 3?

The Form 3 lists several stock options to buy Belite Bio ordinary shares at exercise prices from $0.4386 to $158.36. Each grant specifies an expiration date between 2030 and 2036, outlining a long-dated incentive package tied to the company’s share performance.

How many Belite Bio (BLTE) American depositary shares does the CFO hold?

The filing shows direct ownership of 100,000 American depositary shares. A footnote explains that each ADS represents one ordinary share of Belite Bio, so this position corresponds economically to 100,000 ordinary shares, in addition to his separately listed ordinary share holdings.

What ordinary share holdings does the Belite Bio (BLTE) CFO disclose?

Beyond options and ADSs, the Form 3 reports direct ownership of 195,264 ordinary shares. This figure reflects his current common equity stake, separate from the additional ordinary shares that could be acquired in the future through his various stock option grants.

How do the Belite Bio (BLTE) CFO’s option grants vest over time?

Footnotes describe specific vesting schedules. Some options, such as those for 144,868 and 26,112 ordinary shares, were fully vested before March 18, 2026, while others vest monthly over 36 months or in annual tranches through 2029, contingent on continued service.

What is the ADS-to-ordinary share ratio for Belite Bio (BLTE) in this filing?

A footnote states that each American depositary share represents one ordinary share with par value $0.0001. This 1:1 ratio helps investors compare the CFO’s ADS holdings directly with his ordinary share and option positions on an equivalent share basis.